

In-Clinic Guide to Medical Management of Pediatric Overweight and Obesity⁴

Overweight and Obesity	Dyslipidemia ²												
<p>Weight _____ Height _____ Height percentile _____ BMI _____ BMI percentile _____ BP _____ BP percentile _____</p> <p>Labs:</p> <p>If BMI is 85th-94th percentile <u>without</u> Risk Factors*</p> <ul style="list-style-type: none"> Fasting lipid profile <p>If BMI is 85th-94th percentile <u>with</u> ≥1 Risk Factor(s)* and ≥ 10 y.o.</p> <ul style="list-style-type: none"> Fasting lipid profile ALT and AST Hgb A1C³ ♦ <p>*Risk Factors</p> <table border="0"> <tr> <td>1st or 2nd degree FHx:</td> <td>Patient Medical Hx:</td> </tr> <tr> <td>Early CVD</td> <td>Acanthosis Nigricans</td> </tr> <tr> <td>Hyperlipidemia</td> <td>Elevated BP</td> </tr> <tr> <td>T2DM</td> <td>PCOS</td> </tr> <tr> <td>Overweight or obesity</td> <td>Tobacco use</td> </tr> <tr> <td>HTN</td> <td>Race/ethnicity (Hispanic, NA, AA)</td> </tr> </table> <p>If BMI is ≥95th percentile and ≥ 10 y.o. <u>without</u> Risk Factors*</p> <ul style="list-style-type: none"> Fasting lipid profile ALT and AST Hgb A1C³ ♦ <p>♦ NOTE: 2-hr glucose challenge (OGTT) is the preferred test for diagnosing impaired glucose tolerance.¹</p>	1st or 2nd degree FHx:	Patient Medical Hx:	Early CVD	Acanthosis Nigricans	Hyperlipidemia	Elevated BP	T2DM	PCOS	Overweight or obesity	Tobacco use	HTN	Race/ethnicity (Hispanic, NA, AA)	<p>First Screen (fasting lipid profile): Recommended when child is between 2 and 10 y.o. with 1 of the following: FHx Risk (in 1ST or 2ND degree relative)</p> <ul style="list-style-type: none"> Dyslipidemia (Tchol >240mg/dL) CV event before 55 y.o. (men), 65 y.o. (women) Unknown FHx <p>Patient Risk</p> <ul style="list-style-type: none"> BMI ≥85th percentile Diabetes HTN (Stage 1 or greater) PCOS Tobacco use <p>If normal, repeat every 3-5 years</p> <p>Intervention</p> <ul style="list-style-type: none"> LDL <110 mg/dL is ideal Lifestyle intervention includes diet, exercise, weight management Consider medication if ≥ 8 y.o. and LDL is: ≥ 190 mg/dL, or ≥ 160 mg/dL with 2 risk factors or FHx of early CVD ≥ 130 mg/dL with diabetes For high triglycerides or low HDL: Weight management and exercise Isolated fasting triglycerides >400 mg/dL: Begin medication
1st or 2nd degree FHx:	Patient Medical Hx:												
Early CVD	Acanthosis Nigricans												
Hyperlipidemia	Elevated BP												
T2DM	PCOS												
Overweight or obesity	Tobacco use												
HTN	Race/ethnicity (Hispanic, NA, AA)												
<p>Assessment and Interventions</p> <ul style="list-style-type: none"> Assess dietary and activity habits Use an encounter form to assess readiness to change and make goals Use Motivational Interviewing approach <ul style="list-style-type: none"> Ask permission to discuss weight Practice reflective listening Identify “change talk” Affirm feelings and positions Summarize stated plan 	<p>Evidence-Based Interventions</p> <p>Assist patient to select specific lifestyle change goal:</p> <p>KEY MESSAGES:</p> <p>7: Eat breakfast 7 days a week</p> <p>5: Eat 5 fruits and vegetables every day</p> <p>2: Screen time (TV, video, computer) is no more than 2 hours per day</p> <p>1: Exercise at least 1 hour every day</p> <p>0: No sweetened drinks</p>												

¹ American Diabetes Association (2002). Screening for diabetes. *Diabetes Care*, 25(s1). s 21-s24. doi: 10.2337/diacare.25.2007.S21

² Daniels S.R. & Greer, F.R. (2008). Lipid screening and cardiovascular health in childhood. *Pediatrics*, 122(1), 198-205. doi: 10.1542/peds.2008-1349.

³ The International Expert Committee (2009). International expert committee report on the role of the A1C assay in the diagnosis of diabetes, *Diabetes Care*, 32(7). 1-8. doi: 10.2337/dc09-903

⁴ Krebs, N. F., Himes J.H., Jacobson D., Nicklas T.A Guilday P., & Styne, D. (2007). Assessment of child and adolescent overweight and obesity. *Pediatrics*, 120; S193-S228. doi: 10.1542/peds.2007-2329D.

5. **Hypertension Work Up** ¹ (using appropriate size cuff at heart level on a calm child)

		Pre-Hypertension	Stage 1 HTN	Stage 2 HTN
Definition	BPs on 3 different occasions systolic OR diastolic	≥90 th % - <95 th %	95 th % - 5mm Hg above 99 th %	> 5mm Hg above 99 th %
Evaluation	UA / UC		✓	✓
	BUN/CR, lytes		✓	✓
	CBC		✓	✓
	Renal ultrasound		✓	✓
	ECHO cardiogram		✓	✓
	Retinal exam (referral)		✓	✓
	Further imaging and labs			Refer to Peds HTN w/in 2 wks. Immediately, if symptomatic
Lifestyle Modifications	Weight loss, if indicated	✓	✓	✓
	Exercise, 30-60 mins/d	✓	✓	✓
	Decrease sedentary activities	✓	✓	✓
	DASH diet	✓	www.nhlbi.nih.gov/health/public/heart/hbp/dash/new_dash.pdf	✓
	Tobacco cessation	✓	✓	✓
Medications IF...	(Refer as needed)	Existing co-morbidities (diabetes, chronic renal or cardiac disease)	<ul style="list-style-type: none"> End organ damage HTN is secondary Symptomatic Diabetes, type 1 or 2 <ul style="list-style-type: none"> Persistent despite 6 mo of lifestyle modification 	Always
Follow- up		In 6 months	Regularly/Refer if meds required	Frequently until stabilized

Polycystic Ovary Syndrome (PCOS) ²

<p>Definition:</p> <ul style="list-style-type: none"> Persistent anovulation Lab or clinical evidence of hyperandrogenism History: Menses FHx of PCOS Premature adrenarche Rapidity of onset of androgenic changes Hirsutism – any depilatory measures 	<p>Physical Exam:</p> <ul style="list-style-type: none"> Hirsutism Acne Clitoromegally Virilization Premature adrenarche if pre-menarchal 	<p>Evaluation:</p> <ul style="list-style-type: none"> TSH, Prolactin, Pregnancy test Lipid profile, fasting If amenorrheic: Provera challenge (10 mg Provera qd x 10d) +/- Total testosterone +/- DHEA-S +/- 17-OH progesterone, 8am and fasting If sx's of Cushing's: dexamethasone suppression test If obesity/acanthosis: fasting and/or 2 hr glucose as in obesity protocol 	<p>Treatment:</p> <ul style="list-style-type: none"> Weight loss, if indicated Estrogen/progesterone combo (OCP, patch, ring) Consider metformin Refer for severe or recalcitrant hirsutism
---	---	--	--

¹ The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents: Pediatrics Vol. 114 No. 2 August 2004, pp. 555-576

² Speroff and Fritz, 2005; AACE. *Endocrin Pract.* 2005